A Closer Look at AbbVie's Options Market Dynamics
HSBC Adjusts Price Target on AbbVie to $215 From $185
Favorite High-yield Dividend Stocks - BMO
Cerevel Therapeutics Ticks Higher Amid Nasdaq Delisting Notice for AbbVie Deal
How To Earn $100 Per Month From AbbVie Stock
Express News | Abbvie Inc : HSBC Raises Target Price to $215 From $185
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Two Hot Stocks: AbbVie and IBM
Evercore Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $192
BNP Paribas Exane Adjusts Price Target on AbbVie to $193 From $172
Investors Heavily Search AbbVie Inc. (ABBV): Here Is What You Need to Know
Evercore ISI Sticks to Its Buy Rating for AbbVie (ABBV)
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), AbbVie (ABBV)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), AptarGroup (ATR) and AbbVie (ABBV)
Allergan Aesthetics Celebrates the Second Annual JUVÉDERM Day
USA pharmaceutical stocks 'switching trading': two weight-loss giants fall, while stagnant giants rise in turn.
The rotation of this stock price is not only due to momentum effects, but also because the USA pharmaceutical industry seems to have responded well to the regulatory pressure brought by the Inflation Reduction Act.
Express News | Abbvie : Guggenheim Raises Target Price to $212 From $190
Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ
AbbVie's Class I new drug for AIDS has been approved for clinical use in China.
On July 29th, China's National Medical Products Administration Pharmaceutical Evaluation Center (CDE) announced on its official website that AbbVie's (ABBV.US) Class 1 new drug ABBV-382 injection has been approved for clinical use.
Most U.S. Pharmas Don't Pay Any U.S. Income Tax